ALDX Aldeyra Therapeutics: Earnings growth forecast for next year

Symbol and logo of brand Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics (ALDX) relies on competent management with transparent relations with the FDA. The monopoly status of its unique eye drops will allow the company to independently determine the cost of therapy. This 12-month EPS growth chart demonstrates scaling potential, where 15.30 serves as the base parameter value. High readiness of contract manufacturing plants guarantees the rapid ramp-up of molecule synthesis without downtime.

Aldeyra Therapeutics Inc. (ALDX): Net earnings per share growth forecast for next year from 07/04/2022 to 11/16/2026

Metric breakdowns and analytics for Aldeyra Therapeutics (ALDX)

Fundamental company analysis:ALDX, Aldeyra Therapeutics Inc.
Finished products of Aldeyra

The metric is calculated as the weighted average of analysts' expectations for the change in earnings per share next year relative to current values. This indicator filters out market noise, identifying a steady professional consensus regarding future returns. For Aldeyra Therapeutics (ALDX), such forecasts depend directly on the successful certification of innovative ophthalmological drugs. The price action of the forward net income growth rate reflects market confidence in overcoming regulatory barriers.

Competitor analysis for Aldeyra Therapeutics

ALC (Alcon Corp) - Earnings growth forecast for next year|Bausch + Lomb Corporation (BLCO) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year GKOS|Earnings growth forecast for next year Apellis Pharmaceuticals, Inc. (APLS)|Earnings growth forecast for next year BLTE (Belite Bio)|OCUL - Expected earnings per share growth for next year|HROW - Net earnings per share growth forecast for next year|Expected earnings per share trend next year VRDN (Viridian Therapeutics)|LENZ (LENZ Therapeutics, Inc.) - Expected earnings per share growth for next year|Oculis Holding AG - Expected earnings per share trend next year|Net earnings per share growth forecast for next year eyepointpharma.com|Earnings growth forecast for next year Kodiak Sciences Inc.|Earnings growth forecast for next year KALA|IRD - Expected net earnings per share growth next year|Earnings growth forecast for next year OKYO (OKYO Pharma Limited)|ADVM - Expected earnings per share growth for next year|OTLK: Expected earnings per share growth for next year|CLSD (Clearside) - Projected earnings per share growth rate for next year|NBY: Earnings growth forecast for next year|Kiora Pharma (KPRX) - Earnings growth forecast for next year|ALIM (alimerasciences.com) - Earnings growth forecast for next year|eyenovia.com (EYEN) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year GHSI|OCUP (Ocuphire) - Expected earnings per share trend next year|Earnings growth forecast for next year OPT (Opthea Ltd)